Current Oncology (Feb 2023)

Application of CRISPR/Cas9 Technology in Cancer Treatment: A Future Direction

  • Ali A. Rabaan,
  • Hajir AlSaihati,
  • Rehab Bukhamsin,
  • Muhammed A. Bakhrebah,
  • Majed S. Nassar,
  • Abdulmonem A. Alsaleh,
  • Yousef N. Alhashem,
  • Ammar Y. Bukhamseen,
  • Khalil Al-Ruhimy,
  • Mohammed Alotaibi,
  • Roua A. Alsubki,
  • Hejji E. Alahmed,
  • Saleh Al-Abdulhadi,
  • Fatemah A. Alhashem,
  • Ahlam A. Alqatari,
  • Ahmed Alsayyah,
  • Ramadan Abdelmoez Farahat,
  • Rwaa H. Abdulal,
  • Ali H. Al-Ahmed,
  • Mohd. Imran,
  • Ranjan K. Mohapatra

DOI
https://doi.org/10.3390/curroncol30020152
Journal volume & issue
Vol. 30, no. 2
pp. 1954 – 1976

Abstract

Read online

Gene editing, especially with clustered regularly interspaced short palindromic repeats associated protein 9 (CRISPR-Cas9), has advanced gene function science. Gene editing’s rapid advancement has increased its medical/clinical value. Due to its great specificity and efficiency, CRISPR/Cas9 can accurately and swiftly screen the whole genome. This simplifies disease-specific gene therapy. To study tumor origins, development, and metastasis, CRISPR/Cas9 can change genomes. In recent years, tumor treatment research has increasingly employed this method. CRISPR/Cas9 can treat cancer by removing genes or correcting mutations. Numerous preliminary tumor treatment studies have been conducted in relevant fields. CRISPR/Cas9 may treat gene-level tumors. CRISPR/Cas9-based personalized and targeted medicines may shape tumor treatment. This review examines CRISPR/Cas9 for tumor therapy research, which will be helpful in providing references for future studies on the pathogenesis of malignancy and its treatment.

Keywords